2/25
10:10 am
BEAM
Rating for BEAM
High
Report
Rating for BEAM
2/25
10:10 am
BEAM
Rating for BEAM
High
Report
Rating for BEAM
2/25
08:23 am
BEAM
Rating for BEAM
Medium
Report
Rating for BEAM
2/25
08:23 am
BEAM
Rating for BEAM
Medium
Report
Rating for BEAM
2/20
03:50 pm
BEAM
Rating for BEAM
Low
Report
Rating for BEAM
2/20
06:51 am
BEAM
Beam Therapeutics initiated with a Buy at Canaccord
Medium
Report
Beam Therapeutics initiated with a Buy at Canaccord
2/20
06:29 am
BEAM
Beam Therapeutics initiated with a Buy at Canaccord
Low
Report
Beam Therapeutics initiated with a Buy at Canaccord
1/21
10:11 am
BEAM
Rating for BEAM
Low
Report
Rating for BEAM
1/21
10:11 am
BEAM
Rating for BEAM
Low
Report
Rating for BEAM
1/20
07:09 pm
BEAM
Beam Therapeutics (NASDAQ:BEAM) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Beam Therapeutics (NASDAQ:BEAM) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
1/9
06:10 am
BEAM
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.
1/7
03:16 pm
BEAM
Rating for BEAM
Low
Report
Rating for BEAM
1/7
08:18 am
BEAM
Beam Therapeutics initiated with a Neutral at UBS
Low
Report
Beam Therapeutics initiated with a Neutral at UBS
1/7
03:00 am
BEAM
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.
Medium
Report
Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.